Wolfe Research initiated coverage of Insmed with an Outperform rating and $42 price target. The firm sees a “highly favorable” risk/reward for the brensocatib Phase 3 ASPEN readout likely in Q2, the analyst tells investors in a research note. Possibly due to the somewhat weak Phase 2 readout, the market appears to be only valuing brensocatib at a 35% probability of success, Wolfe added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSM: